Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0Frontiers in Stroke

Cytoflavin's neuroprotective effect in acute ischemic stroke: a systematic review and meta-analysis

  1. 1Department of Neurology, Faculty of Medicine, University of Diponegoro, Semarang, Indonesia

Abstract

Acute ischemic stroke (AIS) remains a leading cause of long-term disability globally. While reperfusion therapies are effective, there is a growing need for adjunct neuroprotective strategies to minimize secondary brain injury. Cytoflavin, a metabolic and antioxidant compound, has shown potential neuroprotective effects. However, its clinical efficacy remains underexplored. This systematic review and meta-analysis aim to evaluate the efficacy of Cytoflavin in AIS, focusing on neurological recovery (NIHSS), functional independence (Barthel Index), cognitive performance (MMSE), and infarct volume. A systematic search was conducted across multiple databases for studies evaluating Cytoflavin in AIS. Nine studies were included, with a combined enrollment of 3,254 participants across treatment arms (sample sizes reported per arm); the number of unique participants contributing to each pooled outcome was smaller after correcting for shared control groups and repeated-measures overlap across evaluation time points (e.g., 1,379 for NIHSS). Data were analyzed using random-effects models; where a shared control group was compared against two Cytoflavin dose arms within the same study, the control group was split proportionally between the two comparisons to avoid double-counting participants (unit-of-analysis correction). Risk of bias was assessed using Cochrane Risk of Bias tool and Newcastle-Ottawa Scale. Cytoflavin significantly improved NIHSS scores (MD = −2.63, 95% CI: −3.15 to −2.10; moderate certainty) and Barthel Index (MD = 19.29, 95% CI: 9.52 to 29.07; moderate certainty), and showed improvements of low certainty in MMSE scores (MD = +6.93, 95% CI: 1.39 to 12.47) and mRS scores (MD = −0.41, 95% CI: −0.74 to −0.09), the latter derived from continuous summary statistics for an inherently ordinal scale (see Limitations). For infarct volume, effects diverged by evaluation time point: a marginal increase was observed at Day-10 (MD = +0.17 cm3, based on a single study), while a non-significant reduction was observed at Day-21 (MD = −4.73 cm3, 95% CI: −11.41 to 1.95; very low certainty). High heterogeneity (I2 ranging from 0% to 100%) was observed across outcomes and persisted after the unit-of-analysis correction, indicating genuine clinical and methodological diversity across studies. In conclusion, cytoflavin shows promising neuroprotective effects in AIS. However, due to heterogeneity and methodological limitations, further large-scale, high-quality studies are needed to confirm its efficacy and optimize treatment protocols.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251112430, identifier: CRD420251112430.

Related

  1. Effects of Metformin on Clinical Outcomes After Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Ting-Yen Chen, Yu-Chi Su, Yu-Ching Lin
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Photothrombotic Ischemic Stroke in Rats: A Systematic Review of Experimental Parameters and Therapeutic Applications in Neuroprotection, Neuromodulation, and Post-Stroke Recovery
    Giovanna R. Raci, Fernando A. Oliveira, Nicole M. E. Valle +7
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Neuroprotective Mechanisms of Sinomenine in Ischemic Stroke: The Role of Fermt2 in Neuroinflammation.
    Jie Yan, Wenjuan Li, Tian Qin +4
    InflammationPeer-reviewedCC BY-NC-NDFull textNeurologyEurope PMCPMC
  4. Novel adamantane-nitrone hybrids: design, synthesis, and their multi-target neuroprotective effects against ischemic stroke
    Hao Lu, Jiaxin Zheng, Ningning Luo +6
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textNeurologyCrossrefEurope PMCPMCEurope PMC
  5. Benefit Expectations and Neuroprotective Prescribing for Acute Ischemic Stroke in China
    Z. Tan, L. Liu, A. Wang +6
    medRxivPreprintCC BY-NC-NDFull textNeurologymedRxiv
BibTeX
@article{retnaningsih2026cytoflavins,
  title = {{Cytoflavin's neuroprotective effect in acute ischemic stroke: a systematic review and meta-analysis}},
  author = {Retnaningsih Retnaningsih and Dodik Tugasworo and Wati Arinta Puspita and Chandra Elvika and Arrizki Azka Pratama},
  journal = {Frontiers in Stroke},
  year = {2026},
  month = oct,
  doi = {10.3389/fstro.2026.1775376},
  url = {https://doi.org/10.3389/fstro.2026.1775376},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Cytoflavin's neuroprotective effect in acute ischemic stroke: a systematic review and meta-analysis
AU  - Retnaningsih Retnaningsih
AU  - Dodik Tugasworo
AU  - Wati Arinta Puspita
AU  - Chandra Elvika
AU  - Arrizki Azka Pratama
PY  - 2026
DA  - 2026/10/30
JO  - Frontiers in Stroke
DO  - 10.3389/fstro.2026.1775376
UR  - https://doi.org/10.3389/fstro.2026.1775376
AB  - Acute ischemic stroke (AIS) remains a leading cause of long-term disability globally. While reperfusion therapies are effective, there is a growing need for adjunct neuroprotective strategies to minimize secondary brain injury. Cytoflavin, a metabolic and antioxidant compound, has shown potential neuroprotective effects. However, its clinical efficacy remains underexplored. This systematic review and meta-analysis aim to evaluate the efficacy of Cytoflavin in AIS, focusing on neurological recovery (NIHSS), functional independence (Barthel Index), cognitive performance (MMSE), and infarct volume. A systematic search was conducted across multiple databases for studies evaluating Cytoflavin in AIS. Nine studies were included, with a combined enrollment of 3,254 participants across treatment arms (sample sizes reported per arm); the number of unique participants contributing to each pooled outcome was smaller after correcting for shared control groups and repeated-measures overlap across evaluation time points (e.g., 1,379 for NIHSS). Data were analyzed using random-effects models; where a shared control group was compared against two Cytoflavin dose arms within the same study, the control group was split proportionally between the two comparisons to avoid double-counting participants (unit-of-analysis correction). Risk of bias was assessed using Cochrane Risk of Bias tool and Newcastle-Ottawa Scale. Cytoflavin significantly improved NIHSS scores (MD = −2.63, 95% CI: −3.15 to −2.10; moderate certainty) and Barthel Index (MD = 19.29, 95% CI: 9.52 to 29.07; moderate certainty), and showed improvements of low certainty in MMSE scores (MD = +6.93, 95% CI: 1.39 to 12.47) and mRS scores (MD = −0.41, 95% CI: −0.74 to −0.09), the latter derived from continuous summary statistics for an inherently ordinal scale (see Limitations). For infarct volume, effects diverged by evaluation time point: a marginal increase was observed at Day-10 (MD = +0.17 cm3, based on a single study), while a non-significant reduction was observed at Day-21 (MD = −4.73 cm3, 95% CI: −11.41 to 1.95; very low certainty). High heterogeneity (I2 ranging from 0% to 100%) was observed across outcomes and persisted after the unit-of-analysis correction, indicating genuine clinical and methodological diversity across studies. In conclusion, cytoflavin shows promising neuroprotective effects in AIS. However, due to heterogeneity and methodological limitations, further large-scale, high-quality studies are needed to confirm its efficacy and optimize treatment protocols.  Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251112430, identifier: CRD420251112430.
SN  - 2813-3056
ER  -